Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.
Video Library
Search the Video Library
Video Language
Filter by Cancer Type:
Displaying Results 1 - 15 of 37
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
GRACE sat down with Dr. Marco Ruiz to discuss information regarding acute myeloid leukemia (AML) in elderly patients (Leucemia aguda mieloide (LMA) en la población de tercera edad). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer
GRACE sat down with Dr. Marco Ruiz to discuss information regarding when and who to refer for hematopoietic cell transplantation (HCT) (¿Cuándo y para quién se recomienda el trasplante de células hematopoyéticas (TCH)?). Stay tuned for more on our continuing video series with our Spanish speaking
GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of fms related tyrosine kinase 3 (flt3) and myeloproliferative neoplasms (MPN) mutations in acute myeloid leukemia (AML) (¿Cuál es el rol de la tirosina cinasa 3 afín a FMS (FLT3) y de las mutaciones en las neoplasias
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses chemotherapy and immunotherapy combinations in advanced squamous non-small cell lung cancer. We thank
For our Mandarin-speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our Lung Cancer Video Library. In this video translation, Dr. Li discusses consolidation radiation after a good response to first-line therapy. We would
For our Mandarin speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our Lung Cancer Video Library. In this video translation, Dr. Li discusses evolving standards for molecular testing in advanced NSCLC. We would like to
For our Mandarin speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our Lung Cancer Video Library. In this video translation, Dr. Li discusses the current status of Tumor Mutation Burden (TMB). We would like to thank the
Dr. Sandip Patel, Associate Professor of Medicine at the Moores Cancer Center, UC San Diego Health, joined GRACE to offer updates to our Lung Cancer Video Library. In this video, Dr. Patel discusses the current status of tumor mutation burden. We thank the following organizations for their support
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li shares information on the leading treatment options for patients with advanced NSCLC and high tumor PD-L1 expression. To join
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li shares information on the leading treatment options for patients with low or negative tumor PD-L1 expression and advanced non
For this addition to the Lung Cancer Video Library, Dr. Millie Das joins GRACE to discuss current updates in treatment options for non small cell lung cancer. In this video, Dr. Das discusses the current leading treatment options for patients with low or negative tumor PDL1 expression and advanced
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li discusses the leading treatment options for patients with low or negative tumor PD-L1 expression and advanced squamous NSCLC